NASDAQ:THTX

Delisted

Theratechnologies Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy THTX

*Your capital is at risk

$3.39

+0 (+0%)

At Close: Dec 24, 2025

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

07:30am, Monday, 09'th Dec 2024

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with compl

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

07:30am, Wednesday, 04'th Dec 2024

Addition of investigational RNA-targeted medicines build upon Theratechnologies' foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Th

Theratechnologies Announces Resumed Production of EGRIFTA SV®

04:30pm, Tuesday, 03'rd Dec 2024

MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c

Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

07:30am, Monday, 02'nd Dec 2024

MONTREAL, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

07:30am, Tuesday, 26'th Nov 2024

Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV ® with simplified dosing for the treatment of excess abdominal fat in ad

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

02:00pm, Thursday, 17'th Oct 2024

MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and comme

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

07:30am, Thursday, 17'th Oct 2024

Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens Baseline Data Show More Frequent Selection of Ibalizumab i

Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript

10:48am, Thursday, 10'th Oct 2024

Theratechnologies Inc. (NASDAQ:THTX ) Q2 2024 Earnings Conference Call October 10, 2024 8:30 AM ET Company Participants Julie Schneiderman - Senior Director, Communications & Corporate Affairs Paul Le

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

07:30am, Thursday, 10'th Oct 2024

MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

07:30am, Wednesday, 09'th Oct 2024

MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and comme

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by